

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED

精優藥業控股有限公司*

(incorporated in Bermuda with limited liability)

(Stock Code: 00858)

DELAY IN DESPATCH OF CIRCULAR

Reference is made to the announcements issued by the Company dated 23 February 2013 and 27 February 2013 in relation to the Acquisition (the “**Announcements**”). Terms used herein shall have the same meanings as those defined in the Announcements unless defined otherwise.

As disclosed in the Announcements, a circular (the “**Circular**”) containing, among other things, (1) further information on the Acquisition and the Acquisition Agreement; (2) the recommendation of the Independent Board Committee to the Independent Shareholders; (3) the advice from the Independent Financial Advisers to the Independent Board Committee and the Independent Shareholders; and (4) a notice of the SGM, was expected to be despatched by the Company to the Shareholders on or before 30 April 2013.

As additional time is required to finalise the contents of the Circular, the date of despatch of the Circular will have to be postponed to a date on or before 16 May 2013.

By order of the Board
Extrawell Pharmaceutical Holdings Limited
Xie Yi
Director

Hong Kong, 29 April 2013

As at the date of this announcement, the executive directors are Dr. Mao Yumin, Dr. Xie Yi, Dr. Lou Yi and Ms. Wong Sau Kuen and the independent non-executive directors are Mr. Fang Lin Hu, Mr. Xue Jing Lun and Ms. Jin Song.

* For identification purpose only